[1] |
POWELL EE, WONG VWS, RINELLA M. Non-alcoholic fatty liver disease[J]. Lancet, 2021, 397( 10290): 2212- 2224. DOI: 10.1016/S0140-6736(20)32511-3.
|
[2] |
LAZARUS JV, MARK HE, ANSTEE QM, et al. Advancing the global public health agenda for NAFLD: A consensus statement[J]. Nat Rev Gastroenterol Hepatol, 2022, 19( 1): 60- 78. DOI: 10.1038/s41575-021-00523-4.
|
[3] |
ZHOU JH, ZHOU F, WANG WX, et al. Epidemiological features of NAFLD from 1999 to 2018 in China[J]. Hepatology, 2020, 71( 5): 1851- 1864. DOI: 10.1002/hep.31150.
|
[4] |
YANG RX, FAN JG. A new understanding of nonalcoholic fatty liver disease and its rename[J]. J Clin Hepatol, 2023, 39( 8): 1775- 1779. DOI: 10.3969/j.issn.1001-5256.2023.08.002.
杨蕊旭, 范建高. 非酒精性脂肪性肝病新认识与再更名[J]. 临床肝胆病杂志, 2023, 39( 8): 1775- 1779. DOI: 10.3969/j.issn.1001-5256.2023.08.002.
|
[5] |
FANG YL, CHEN H, WANG CL, et al. Pathogenesis of non-alcoholic fatty liver disease in children and adolescence: From“two hit theory” to“multiple hit model”[J]. World J Gastroenterol, 2018, 24( 27): 2974- 2983. DOI: 10.3748/wjg.v24.i27.2974.
|
[6] |
FLESSA CM, KYROU I, NASIRI-ANSARI N, et al. Endoplasmic reticulum stress and autophagy in the pathogenesis of non-alcoholic fatty liver disease(NAFLD): Current evidence and perspectives[J]. Curr Obes Rep, 2021, 10( 2): 134- 161. DOI: 10.1007/s13679-021-00431-3.
|
[7] |
LEBEAUPIN C, VALLÉE D, HAZARI Y, et al. Endoplasmic reticulum stress signalling and the pathogenesis of non-alcoholic fatty liver disease[J]. J Hepatol, 2018, 69( 4): 927- 947. DOI: 10.1016/j.jhep.2018.06.008.
|
[8] |
XIA SW, WANG ZM, SUN SM, et al. Endoplasmic reticulum stress and protein degradation in chronic liver disease[J]. Pharmacol Res, 2020, 161: 105218. DOI: 10.1016/j.phrs.2020.105218.
|
[9] |
CULLINAN SB, ZHANG D, HANNINK M, et al. Nrf2 is a direct PERK substrate and effector of PERK-dependent cell survival[J]. Mol Cell Biol, 2003, 23( 20): 7198- 7209. DOI: 10.1128/MCB.23.20.7198-7209.2003.
|
[10] |
SHEN JS, CHEN X, HENDERSHOT L, et al. ER stress regulation of ATF6 localization by dissociation of BiP/GRP78 binding and unmasking of Golgi localization signals[J]. Dev Cell, 2002, 3( 1): 99- 111. DOI: 10.1016/s1534-5807(02)00203-4.
|
[11] |
MARRA F, SVEGLIATI-BARONI G. Lipotoxicity and the gut-liver axis in NASH pathogenesis[J]. J Hepatol, 2018, 68( 2): 280- 295. DOI: 10.1016/j.jhep.2017.11.014.
|
[12] |
ZHANG KZ, WANG SY, MALHOTRA J, et al. The unfolded protein response transducer IRE1α prevents ER stress-induced hepatic steatosis[J]. EMBO J, 2011, 30( 7): 1357- 1375. DOI: 10.1038/emboj.2011.52.
|
[13] |
LIU CZ, ZHOU B, MENG MY, et al. FOXA3 induction under endoplasmic reticulum stress contributes to non-alcoholic fatty liver disease[J]. J Hepatol, 2021, 75( 1): 150- 162. DOI: 10.1016/j.jhep.2021.01.042.
|
[14] |
XIAO GZ, ZHANG T, YU SB, et al. ATF4 protein deficiency protects against high fructose-induced hypertriglyceridemia in mice[J]. J Biol Chem, 2013, 288( 35): 25350- 25361. DOI: 10.1074/jbc.M113.470526.
|
[15] |
MAO H, CHEN W, CHEN LX, et al. Potential role of mitochondria-associated endoplasmic reticulum membrane proteins in diseases[J]. Biochem Pharmacol, 2022, 199: 115011. DOI: 10.1016/j.bcp.2022.115011.
|
[16] |
CHEN XQ, ZHANG FF, GONG Q, et al. Hepatic ATF6 increases fatty acid oxidation to attenuate hepatic steatosis in mice through peroxisome proliferator-activated receptor Α[J]. Diabetes, 2016, 65( 7): 1904- 1915. DOI: 10.2337/db15-1637.
|
[17] |
YAMAZAKI H, HIRAMATSU N, HAYAKAWA K, et al. Activation of the Akt-NF-kappaB pathway by subtilase cytotoxin through the ATF6 branch of the unfolded protein response[J]. J Immunol, 2009, 183( 2): 1480- 1487. DOI: 10.4049/jimmunol.0900017.
|
[18] |
CHEN J, ZHANG MH, ZHU MM, et al. Paeoniflorin prevents endoplasmic reticulum stress-associated inflammation in lipopolysaccharide-stimulated human umbilical vein endothelial cells via the IRE1α/NF-κB signaling pathway[J]. Food Funct, 2018, 9( 4): 2386- 2397. DOI: 10.1039/c7fo01406f.
|
[19] |
LEI N, SONG HF, ZENG L, et al. Persistent lipid accumulation leads to persistent exacerbation of endoplasmic reticulum stress and inflammation in progressive NASH via the IRE1α/TRAF2 complex[J]. Molecules, 2023, 28( 7): 3185. DOI: 10.3390/molecules28073185.
|
[20] |
LEBEAUPIN C, PROICS E, de BIEVILLE CH, et al. ER stress induces NLRP3 inflammasome activation and hepatocyte death[J]. Cell Death Dis, 2015, 6( 9): e1879. DOI: 10.1038/cddis.2015.248.
|
[21] |
LATIF MU, SCHMIDT GE, MERCAN S, et al. NFATc1 signaling drives chronic ER stress responses to promote NAFLD progression[J]. Gut, 2022, 71( 12): 2561- 2573. DOI: 10.1136/gutjnl-2021-325013.
|
[22] |
GENG YN, FABER KN, de MEIJER VE, et al. How does hepatic lipid accumulation lead to lipotoxicity in non-alcoholic fatty liver disease?[J]. Hepatol Int, 2021, 15( 1): 21- 35. DOI: 10.1007/s12072-020-10121-2.
|
[23] |
SENFT D, RONAI ZA. UPR, autophagy, and mitochondria crosstalk underlies the ER stress response[J]. Trends Biochem Sci, 2015, 40( 3): 141- 148. DOI: 10.1016/j.tibs.2015.01.002.
|
[24] |
GONZÁLEZ-RODRÍGUEZ A, MAYORAL R, AGRA N, et al. Impaired autophagic flux is associated with increased endoplasmic reticulum stress during the development of NAFLD[J]. Cell Death Dis, 2014, 5( 4): e1179. DOI: 10.1038/cddis.2014.162.
|
[25] |
ZHOU YP, ZHONG L, YU SJ, et al. Inhibition of stearoyl-coenzyme A desaturase 1 ameliorates hepatic steatosis by inducing AMPK-mediated lipophagy[J]. Aging, 2020, 12( 8): 7350- 7362. DOI: 10.18632/aging.103082.
|
[26] |
BEIER JI, BANALES JM. Pyroptosis: An inflammatory link between NAFLD and NASH with potential therapeutic implications[J]. J Hepatol, 2018, 68( 4): 643- 645. DOI: 10.1016/j.jhep.2018.01.017.
|
[27] |
JIA Q, WANG J, LI W. Relationship between endoplasmic reticulum stress signaling pathway PERK and atherosclerotic plaque stability[J]. Clin Misdiagnosis Mistherapy, 2023, 36( 12): 56- 61. DOI: 10.3969/j.issn.1002-3429.2023.12.012.
贾乾, 王洁, 李雯. 内质网应激信号通路PERK与动脉粥样硬化斑块稳定性的关系[J]. 临床误诊误治, 2023, 36( 12): 56- 61. DOI: 10.3969/j.issn.1002-3429.2023.12.012.
|
[28] |
DEMIREL-YALCINER T, SOZEN E, OZALTIN E, et al. Alpha-Tocopherol supplementation reduces inflammation and apoptosis in high cholesterol mediated nonalcoholic steatohepatitis[J]. Biofactors, 2021, 47( 3): 403- 413. DOI: 10.1002/biof.1700.
|
[29] |
RUAN L, LI FH, LI SB, et al. Effect of different exercise intensities on hepatocyte apoptosis in HFD-induced NAFLD in rats: The possible role of endoplasmic reticulum stress through the regulation of the IRE1/JNK and eIF2α/CHOP signal pathways[J]. Oxid Med Cell Longev, 2021, 2021: 6378568. DOI: 10.1155/2021/6378568.
|
[30] |
KANDA T, MATSUOKA S, YAMAZAKI M, et al. Apoptosis and non-alcoholic fatty liver diseases[J]. World J Gastroenterol, 2018, 24( 25): 2661- 2672. DOI: 10.3748/wjg.v24.i25.2661.
|
[31] |
MARCHI S, PATERGNANI S, MISSIROLI S, et al. Mitochondrial and endoplasmic reticulum calcium homeostasis and cell death[J]. Cell Calcium, 2018, 69: 62- 72. DOI: 10.1016/j.ceca.2017.05.003.
|
[32] |
YE L, LI XQ, WANG JQ. Association between endoplasmic reticulum stress and ferroptosis in liver diseases[J]. J Clin Hepatol, 2023, 39( 4): 980- 985. DOI: 10.3969/j.issn.1001-5256.2023.04.036.
叶露, 李秀芹, 王建青. 肝脏疾病中内质网应激与铁死亡的关系[J]. 临床肝胆病杂志, 2023, 39( 4): 980- 985. DOI: 10.3969/j.issn.1001-5256.2023.04.036.
|
[33] |
WEI S, QIU TM, WANG NN, et al. Ferroptosis mediated by the interaction between Mfn2 and IREα promotes arsenic-induced nonalcoholic steatohepatitis[J]. Environ Res, 2020, 188: 109824. DOI: 10.1016/j.envres.2020.109824.
|
[34] |
JIANG Z, SUN H, MIAO JE, et al. The natural flavone acacetin protects against high-fat diet-induced lipid accumulation in the liver via the endoplasmic reticulum stress/ferroptosis pathway[J]. Biochem Biophys Res Commun, 2023, 640: 183- 191. DOI: 10.1016/j.bbrc.2022.12.014.
|
[35] |
KISSELEVA T, BRENNER D. Molecular and cellular mechanisms of liver fibrosis and its regression[J]. Nat Rev Gastroenterol Hepatol, 2021, 18( 3): 151- 166. DOI: 10.1038/s41575-020-00372-7.
|
[36] |
HERNÁNDEZ-GEA V, HILSCHER M, ROZENFELD R, et al. Endoplasmic reticulum stress induces fibrogenic activity in hepatic stellate cells through autophagy[J]. J Hepatol, 2013, 59( 1): 98- 104. DOI: 10.1016/j.jhep.2013.02.016.
|
[37] |
ZHANG YQ, WEN J, LIU DQ, et al. Demethylenetetrahydroberberine alleviates nonalcoholic fatty liver disease by inhibiting the NLRP3 inflammasome and oxidative stress in mice[J]. Life Sci, 2021, 281: 119778. DOI: 10.1016/j.lfs.2021.119778.
|
[38] |
YOO T, JOO SK, KIM HJ, et al. Disease-specific eQTL screening reveals an anti-fibrotic effect of AGXT2 in non-alcoholic fatty liver disease[J]. J Hepatol, 2021, 75( 3): 514- 523. DOI: 10.1016/j.jhep.2021.04.011.
|
[39] |
PETITO-DA-SILVA TI, SOUZA-MELLO V, BARBOSA-DA-SILVA S. Empaglifozin mitigates NAFLD in high-fat-fed mice by alleviating insulin resistance, lipogenesis and ER stress[J]. Mol Cell Endocrinol, 2019, 498: 110539. DOI: 10.1016/j.mce.2019.110539.
|
[40] |
NASIRI-ANSARI N, NIKOLOPOULOU C, PAPOUTSI K, et al. Empagliflozin attenuates non-alcoholic fatty liver disease(NAFLD) in high fat diet fed ApoE(-/-) mice by activating autophagy and reducing ER stress and apoptosis[J]. Int J Mol Sci, 2021, 22( 2): 818. DOI: 10.3390/ijms22020818.
|
[41] |
YANG J, AO N, DU J, et al. Protective effect of liraglutide against ER stress in the liver of high-fat diet-induced insulin-resistant rats[J]. Endocrine, 2015, 49( 1): 106- 118. DOI: 10.1007/s12020-014-0480-y.
|
[42] |
MANTOVANI A, PETRACCA G, BEATRICE G, et al. Glucagon-like peptide-1 receptor agonists for treatment of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: An updated meta-analysis of randomized controlled trials[J]. Metabolites, 2021, 11( 2): 73. DOI: 10.3390/metabo11020073.
|
[43] |
MOSBAH I BEN, ALFANY-FERNÁNDEZ I, MARTEL C, et al. Endoplasmic reticulum stress inhibition protects steatotic and non-steatotic livers in partial hepatectomy under ischemia-reperfusion[J]. Cell Death Dis, 2010, 1( 7): e52. DOI: 10.1038/cddis.2010.29.
|
[44] |
OZCAN U, YILMAZ E, OZCAN L, et al. Chemical chaperones reduce ER stress and restore glucose homeostasis in a mouse model of type 2 diabetes[J]. Science, 2006, 313( 5790): 1137- 1140. DOI: 10.1126/science.1128294.
|
[45] |
LOOMBA R, LAWITZ E, MANTRY PS, et al. The ASK1 inhibitor selonsertib in patients with nonalcoholic steatohepatitis: A randomized, phase 2 trial[J]. Hepatology, 2018, 67( 2): 549- 559. DOI: 10.1002/hep.29514.
|